Katherine Stueland Sells 22,307 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CEO Katherine Stueland sold 22,307 shares of the company's stock in a transaction on Monday, November 18th. The shares were sold at an average price of $70.34, for a total transaction of $1,569,074.38. Following the completion of the transaction, the chief executive officer now owns 60,011 shares in the company, valued at approximately $4,221,173.74. This represents a 27.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Katherine Stueland also recently made the following trade(s):

• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The shares were sold at an average price of $70.48, for a total transaction of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total transaction of $143,456.40.
• On Monday, September 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The shares were sold at an average price of $33.33, for a total transaction of $121,287.87.

GeneDx Price Performance

WGS stock traded down $1.55 during trading on Wednesday, reaching $69.49. 163,977 shares of the company were exchanged, compared to its average volume of 449,691. GeneDx Holdings Corp. has a twelve month low of $1.29 and a twelve month high of $89.11. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -22.84 and a beta of 2.11. The company has a 50-day moving average of $57.43 and a two-hundred day moving average of $38.69.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.25. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The company had revenue of $76.90 million during the quarter, compared to the consensus estimate of $64.98 million. During the same period in the prior year, the business earned ($0.82) earnings per share. The company's revenue for the quarter was up 44.3% compared to the same quarter last year. As a group, equities analysts predict that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GeneDx

Large investors have recently bought and sold shares of the company. Barclays PLC boosted its stake in shares of GeneDx by 346.3% during the third quarter. Barclays PLC now owns 18,921 shares of the company's stock valued at $803,000 after purchasing an additional 14,681 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of GeneDx by 8.7% during the third quarter. Geode Capital Management LLC now owns 377,631 shares of the company's stock valued at $16,030,000 after purchasing an additional 30,379 shares in the last quarter. State Street Corp boosted its stake in shares of GeneDx by 18.3% during the third quarter. State Street Corp now owns 314,914 shares of the company's stock valued at $13,365,000 after purchasing an additional 48,735 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in shares of GeneDx during the third quarter valued at about $220,000. Finally, Point72 Asset Management L.P. raised its stake in shares of GeneDx by 87.4% in the third quarter. Point72 Asset Management L.P. now owns 293,671 shares of the company's stock worth $12,463,000 after purchasing an additional 136,926 shares during the last quarter. 61.72% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. BTIG Research boosted their target price on shares of GeneDx from $35.00 to $45.00 and gave the company a "buy" rating in a research report on Wednesday, July 31st. Wells Fargo & Company upped their price objective on shares of GeneDx from $34.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 30th. TD Cowen upped their price objective on shares of GeneDx from $46.00 to $50.00 and gave the stock a "buy" rating in a research report on Wednesday, July 31st. Craig Hallum upped their price objective on shares of GeneDx from $70.00 to $95.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. Finally, The Goldman Sachs Group upped their price objective on shares of GeneDx from $54.00 to $70.00 and gave the stock a "neutral" rating in a research report on Wednesday, October 30th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, GeneDx currently has a consensus rating of "Moderate Buy" and an average price target of $59.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.